Ashton Thomas Private Wealth LLC Acquires Shares of 1,968 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Ashton Thomas Private Wealth LLC bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,968 shares of the medical instruments supplier’s stock, valued at approximately $162,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co grew its holdings in LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after acquiring an additional 6,875 shares during the last quarter. Quantbot Technologies LP grew its stake in shares of LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after purchasing an additional 6,669 shares during the last quarter. Ranger Investment Management L.P. grew its stake in shares of LeMaitre Vascular by 1.5% during the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after purchasing an additional 13,681 shares during the last quarter. Congress Asset Management Co. MA increased its holdings in shares of LeMaitre Vascular by 12.0% in the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after purchasing an additional 71,411 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in LeMaitre Vascular by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after buying an additional 38,303 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Up 1.6 %

Shares of LMAT opened at $88.18 on Friday. The stock has a market cap of $1.98 billion, a P/E ratio of 58.40, a price-to-earnings-growth ratio of 2.32 and a beta of 0.88. LeMaitre Vascular, Inc. has a 1 year low of $44.27 and a 1 year high of $92.90. The stock’s 50-day moving average price is $86.17 and its two-hundred day moving average price is $77.04.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same quarter last year, the firm earned $0.37 EPS. LeMaitre Vascular’s quarterly revenue was up 11.4% compared to the same quarter last year. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.85 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the transaction, the chief executive officer now directly owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The disclosure for this sale can be found here. Insiders sold a total of 43,251 shares of company stock worth $3,714,994 in the last quarter. Corporate insiders own 10.79% of the company’s stock.

Analyst Ratings Changes

LMAT has been the subject of several research reports. JMP Securities lifted their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Lake Street Capital began coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Finally, Roth Mkm restated a “buy” rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $94.40.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.